A Phase 2 interventional study of Roflumilast in Plaque Psoriasis, sponsored by Arcutis Biotherapeutics, Inc.. Completed at 30 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-02.
Sponsored by Arcutis Biotherapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing roflumilast in Psoriasis — 3 open to participants now, 3 under way, none of them phase 3. Roflumilast · Psoriasis.
Among the 17 studies testing roflumilast in Psoriasis, this one is the 5th largest by enrollment, is one of 2 that started in 2018, is one of 7 in phase 2, and was the 4th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →3 of the 17 studies testing roflumilast in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:
Modern Research Associates, PLLC · Sites in United States
Ahmed Ibrahim · Sites in Egypt
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 6 · Phase 4 2
First in 2008; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 332 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 46 across the 17 interventional studies. Of the 13 that completed or were terminated, 9 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 9 most frequent:
Arcutis Biotherapeutics, Inc. is the lead sponsor of 26 studies on the registry; 2 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 20 (83%) have results posted.
12 studies in Psoriasis by Arcutis Biotherapeutics, Inc.: none open now, none under way, none of them phase 3. Of 12 finished, 10 (83%) have results posted.
Among the 12 studies in Psoriasis by Arcutis Biotherapeutics, Inc., this one is the 5th largest by enrollment, is one of 2 that started in 2018, is one of 5 in phase 2, and was the 3rd registered.
Arcutis Biotherapeutics, Inc.’s Psoriasis studies by the year they started, since 2017.
1 of the studies testing roflumilast in Psoriasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07725822Modern Research Associates, PLLCAn Open Label Trial to Evaluate Efficacy and Safety of Roflumilast 0.3% Cream for Chronic Plaque and Nail Psoriasis | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing roflumilast in Psoriasis, from their registry updates:
Among Arcutis Biotherapeutics, Inc.’s 12 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label, long-term safety study of roflumilast (ARQ-151) 0.3% cream in subjects with chronic plaque psoriasis involving up to 25% total Body Surface Area (BSA). Study medication will be applied by the qualifying subjects topically once daily for 52 weeks at home. Periodic clinic visits will include assessments for clinical safety, application site reactions, and disease improvement or progression.
Cohort 1 of this study consisted of participants who previously completed study ARQ-151-201 (NCT03638258), and Cohort 2 consisted of participants who were not previously enrolled in ARQ-151-201.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Known or suspected:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants applied roflumilast (ARQ-151) cream 0.3% once daily for 52 weeks
Drug: Roflumilast
Roflumilast cream 0.3% for topical application
Also known as: ARQ-151
Number of Participants Experiencing ≥1 Treatment-emergent Adverse Event (TEAE)
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. All AEs that began after initiating study treatment (treatment-emergent AEs \[TEAEs\]) in ARQ-151-202 are presented.
Time frame: Up to 52 weeks
Number of Participants Experiencing ≥1 Serious Adverse Event (SAE)
An SAE is any AE that in the view of either the PI or Sponsor, results in any of the following outcomes: Death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect.
Time frame: Up to 52 weeks
Number of Participants With an Investigator Global Assessment (IGA) Score of 'Clear' or 'Almost Clear'
The number of participants with an IGA score of 0 ('clear') or 1 ('almost clear') at Week 12 is reported. The IGA is a 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), and higher scores indicate greater plaque severity.
Time frame: Weeks 12, 24, 36, and 52
Duration of Response in Participants Achieving 'Clear' IGA Score
The median time to re-starting study therapy among participants who achieve a 'clear' IGA score and stop treatment to all lesions is presented.
Time frame: Up to 52 weeks
Number of Participants With Intertriginous Area Involvement Achieving an Intertriginous Area Investigator Global Assessment (I-IGA) Score of "Clear' or 'Almost Clear'
The number of participants who had intertriginous area involvement with an I-IGA score of 'clear' or 'almost clear' is presented. The I-IGA is 5-point scale assessing the severity of plaque psoriasis in the intertriginous area, with scores ranging from 0 ('clear') to 4 ('severe'), and higher scores indicate greater plaque severity.
Time frame: Weeks 12, 24, 36, and 52
Number of Participants Achieving a 75% Reduction From Baseline in Modified Psoriasis Severity Index (mPASI-75)
The number of participants achieving a 75% reduction in mPASI (eg, mPASI-75) score relative to baseline is presented. The mPASI combines the assessment of the severity of lesions and the area affected into a single score ranging from 0 ('no disease') to 72 ('maximal disease'), with higher scores indicating greater severity.
Time frame: Baseline and Weeks 12, 24, 36, and 52
Participants were recruited at 30 study sites in the United States and Canada.
| Milestone | Cohort 1: Study 201 Participants | Cohort 2: Non-study 201 Participants |
|---|---|---|
| Started | 230 | 102 |
| Completed | 164 | 80 |
| Not completed | 66 | 22 |
| Withdrew: Adverse event | 11 | 2 |
| Withdrew: Lost to follow-up | 24 | 10 |
| Withdrew: Withdrawal by subject | 26 | 10 |
| Withdrew: Lack of efficacy | 3 | 0 |
| Withdrew: Covid-19 disruption | 2 | 0 |
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. All AEs that began after initiating study treatment (treatment-emergent AEs \[TEAEs\]) in ARQ-151-202 are presented.
| Participants | Cohort 1: Study 201 Participants | Cohort 2: Non-study 201 Participants |
|---|---|---|
| Number of Participants Experiencing ≥1 Treatment-emergent Adverse Event (TEAE) | 104 | 60 |
An SAE is any AE that in the view of either the PI or Sponsor, results in any of the following outcomes: Death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect.
| Participants | Cohort 1: Study 201 Participants | Cohort 2: Non-study 201 Participants |
|---|---|---|
| Number of Participants Experiencing ≥1 Serious Adverse Event (SAE) | 8 | 2 |
The number of participants with an IGA score of 0 ('clear') or 1 ('almost clear') at Week 12 is reported. The IGA is a 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), and higher scores indicate greater plaque severity.
| Participants | Cohort 1: Study 201 Participants | Cohort 2: Non-study 201 Participants |
|---|---|---|
| Week 12 | 92 | 47 |
| Week 24 | 79 | 34 |
| Week 36 | 68 | 36 |
| Week 52 | 68 | 39 |
The median time to re-starting study therapy among participants who achieve a 'clear' IGA score and stop treatment to all lesions is presented.
| weeks | Cohort 1: Study 201 Participants | Cohort 2: Non-study 201 Participants |
|---|---|---|
| Duration of Response in Participants Achieving 'Clear' IGA Score | 8.0 (4.1 to 9.0) | 12.4 (3.0 to NA) |
The number of participants who had intertriginous area involvement with an I-IGA score of 'clear' or 'almost clear' is presented. The I-IGA is 5-point scale assessing the severity of plaque psoriasis in the intertriginous area, with scores ranging from 0 ('clear') to 4 ('severe'), and higher scores indicate greater plaque severity.
| Participants | Cohort 1: Study 201 Participants | Cohort 2: Non-study 201 Participants |
|---|---|---|
| Week 12 | 11 | 15 |
| Week 24 | 13 | 14 |
| Week 36 | 13 | 10 |
| Week 52 | 9 | 10 |
The number of participants achieving a 75% reduction in mPASI (eg, mPASI-75) score relative to baseline is presented. The mPASI combines the assessment of the severity of lesions and the area affected into a single score ranging from 0 ('no disease') to 72 ('maximal disease'), with higher scores indicating greater severity.
| Participants | Cohort 1: Study 201 Participants | Cohort 2: Non-study 201 Participants |
|---|---|---|
| Week 12 | 67 | 63 |
| Week 24 | 114 | 57 |
| Week 36 | 130 | 55 |
| Week 52 | 124 | 61 |
Collected over Up to 52 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Study 201 Participants | 0/230 (0%) | 8/230 (3.5%) | 15/230 (6.5%) |
| Cohort 2: Non-study 201 Participants | 0/102 (0%) | 2/102 (2%) | 7/102 (6.9%) |
| Event | Cohort 1: Study 201 Participants | Cohort 2: Non-study 201 Participants |
|---|---|---|
| Supraventricular tachycardiaCardiac disorders | 0/230 | 1/102 |
| Device failureProduct Issues | 0/230 | 1/102 |
| Atrioventricular block completeCardiac disorders | 1/230 | 0/102 |
| Cardiac failure congestiveCardiac disorders | 1/230 | 0/102 |
| Myocardial infarctionCardiac disorders | 1/230 | 0/102 |
| IleusGastrointestinal disorders | 1/230 | 0/102 |
| SepsisInfections and infestations | 1/230 | 0/102 |
| Femur fractureInjury, poisoning and procedural complications | 1/230 | 0/102 |
| SARS-CoV-2 test positiveInvestigations | 1/230 | 0/102 |
| HyponatraemiaMetabolism and nutrition disorders | 1/230 | 0/102 |
| Event | Cohort 1: Study 201 Participants | Cohort 2: Non-study 201 Participants |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 15/230 | 7/102 |
Baseline was defined as the last observation prior to administration of ARQ-151 cream. Thus the baseline assessments for participants in Cohort 1 assigned to ARQ-151 cream occurred in the ARQ-151-201 study, whereas baseline occurred in this study (ARQ-151-202) for vehicle cream participants in the 201 study and Cohort 2 participants.
| Age, Continuous(years) | Cohort 1: Study 201 Participants | Cohort 2: Non-study 201 Participants | Total |
|---|---|---|---|
| Mean | 55.3 ± 13.52 | 52.7 ± 15.64 | 54.5 ± 14.23 |
| Sex: Female, Male(Participants) | Cohort 1: Study 201 Participants | Cohort 2: Non-study 201 Participants | Total |
|---|---|---|---|
| Female | 104 | 46 | 150 |
| Male | 126 | 56 | 182 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: Study 201 Participants | Cohort 2: Non-study 201 Participants | Total |
|---|---|---|---|
| Hispanic or Latino | 46 | 17 | 63 |
| Not Hispanic or Latino | 184 | 84 | 268 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Cohort 1: Study 201 Participants | Cohort 2: Non-study 201 Participants | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 13 | 6 | 19 |
| Black or African American | 24 | 5 | 29 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| White | 183 | 85 | 268 |
| Multiple/Other | 10 | 5 | 15 |
| Modified Psoriasis Area Severity Index (mPASI)(score on a scale) | Cohort 1: Study 201 Participants | Cohort 2: Non-study 201 Participants | Total |
|---|---|---|---|
| Mean | 5.42 ± 3.700 | 4.50 ± 3.821 | 5.14 ± 3.755 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2018 to primary completion in Oct 2020, 21 months.
Results were first posted in Aug 2022, 1 year 10 months after primary completion. A results delay was requested in Sep 2021.
Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 21 months is above that.
Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Roflumilast
Arcutis Biotherapeutics, Inc. →